IMPL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 Dec 2023 @ 04:58):

Stats
今日成交量	720 030
平均成交量	1.02M
市值	956 000
EPS	$0 ( 2024-03-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0128
ATR14	$0.116 (114.74%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Smith Brandon D	Buy	0
2023-12-15	Vivo Capital Viii, Llc	Sell	87 934	Common Stock
2023-12-18	Vivo Capital Viii, Llc	Sell	209 029	Common Stock
2023-12-19	Vivo Capital Viii, Llc	Sell	208 657	Common Stock
2023-12-15	Vivo Capital Viii, Llc	Sell	12 066	Common Stock

INSIDER POWER
47.38
Last 95 transactions
Buy: 8 739 782 \| Sell: 5 181 184

音量相关性

長: 0.42 (neutral)

短: -0.39 (neutral)

Signal:(41.758) Neutral

Impel Pharmaceuticals 相关性

10 最正相关
FNWB	0.921
EGBN	0.909
CNSL	0.904
DIBS	0.901
ALTO	0.896
FTXO	0.892
FFIC	0.885
FRST	0.883
CSTE	0.881
CCSI	0.88

10 最负相关
LMNR	-0.937
WIRE	-0.927
NRDS	-0.918
MHUA	-0.893
PEGA	-0.892
SKYT	-0.889
OBT	-0.889
MORF	-0.886
HTBI	-0.884
HUGE	-0.882

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Impel Pharmaceuticals 相关性 - 货币/商品

0.11
( neutral )

-0.49
( neutral )

0.00
( neutral )

-0.29
( neutral )

0.08
( neutral )

-0.15
( neutral )

Impel Pharmaceuticals 财务报表

Annual	2022
营收:	$12.65M
毛利润:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2022
营收:	$12.65M
毛利润:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2021
营收:	$668 000
毛利润:	$-23 000.00 (-3.44 %)
EPS:	$-5.25

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Impel Pharmaceuticals

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.